Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

NN-42-1007: First potent and selective hepatic glycogen phosphorylase inhibitor

June 7, 1996

Sanguine's PHER-02 development

June 7, 1996

Amgen initiates first leptin clinical study

June 7, 1996

NO-1886 in phase II clinical trials

June 7, 1996

Sankyo discovers ACAT inhibitor

June 7, 1996

Hoescht reports imidobisphosphonic acid derivatives

June 7, 1996

Fujisawa claims ACAT inhibitors

June 7, 1996

Completion of phase I clinical trials on human red blood cell substitute

May 31, 1996

Celtrix announces the initiation of two phase I trials of SomatoKine

May 31, 1996

ACAT inhibitors from Warner-Lambert

May 31, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 30, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Taiwan biotech looks outward in next phase of growth
BioWorld
Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to...